Ahene Ago, Calonder Claudio, Davis Scott, Kowalchick Joseph, Nakamura Takahiro, Nouri Parya, Vostiar Igor, Wang Yang, Wang Jin
XOMA (US) LLC, Berkeley, California, USA.
AAPS J. 2014 Jan;16(1):164-71. doi: 10.1208/s12248-013-9551-x. Epub 2013 Dec 6.
In recent years, the use of automated sample handling instrumentation has come to the forefront of bioanalytical analysis in order to ensure greater assay consistency and throughput. Since robotic systems are becoming part of everyday analytical procedures, the need for consistent guidance across the pharmaceutical industry has become increasingly important. Pre-existing regulations do not go into sufficient detail in regard to how to handle the use of robotic systems for use with analytical methods, especially large molecule bioanalysis. As a result, Global Bioanalytical Consortium (GBC) Group L5 has put forth specific recommendations for the validation, qualification, and use of robotic systems as part of large molecule bioanalytical analyses in the present white paper. The guidelines presented can be followed to ensure that there is a consistent, transparent methodology that will ensure that robotic systems can be effectively used and documented in a regulated bioanalytical laboratory setting. This will allow for consistent use of robotic sample handling instrumentation as part of large molecule bioanalysis across the globe.
近年来,为确保更高的检测一致性和通量,自动化样本处理仪器的使用已成为生物分析的前沿领域。由于机器人系统正成为日常分析程序的一部分,整个制药行业对统一指导的需求变得越来越重要。现有法规在如何处理将机器人系统用于分析方法,尤其是大分子生物分析方面,没有给出足够详细的规定。因此,全球生物分析联盟(GBC)L5小组在本白皮书中针对机器人系统作为大分子生物分析一部分的验证、鉴定和使用提出了具体建议。遵循所提出的指南可确保有一个一致、透明的方法,以确保机器人系统能在受监管的生物分析实验室环境中得到有效使用和记录。这将使机器人样本处理仪器作为大分子生物分析的一部分在全球范围内得到统一使用。